Here, it will be a key future goal to identify potential determinants of spatially variable tau pathology onset, such as differential gene expression patterns68–70, pre-existing tau pathology (e.g., related to traumatic brain injury)71,72, or premorbid differences and/or heterogeneity in brain network architecture73. The gene discussed is MAPT; the disease is brain injury.